Bladder Urothelial Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: BLD131 MIFTS: 59	Bladder Urothelial Carcinoma Categories: Cancer diseases, Nephrological diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Bladder Urothelial Carcinoma

MalaCards integrated aliases for Bladder Urothelial Carcinoma:

Name: Bladder Urothelial Carcinoma ¹¹ ¹⁴

Transitional Cell Carcinoma of the Bladder ²⁸ ⁵

Transitional Cell Carcinoma of Bladder ¹¹ ⁷¹

Bladder Transitional Cell Carcinoma ¹¹ ¹⁶

Tcc - [transitional Cell Carcinoma] of Bladder ³³

Urinary Bladder Urothelial Carcinoma ¹¹

Carcinoma Transitional Cell Bladder ⁵³

Urothelial Bladder Carcinoma ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Nephrological diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Neoplasms

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms of urinary tract

Malignant neoplasms of bladder

Urothelial carcinoma of bladder

External Ids:

Disease Ontology ¹¹ DOID:4006

NCIt ⁴⁹ C39851

SNOMED-CT ⁶⁸ 393562002

EFO ¹⁶ EFO_0006544

ICD11 ³³ 1237451411

UMLS ⁷¹ C0279680

Sources

Summaries for Bladder Urothelial Carcinoma

Disease Ontology: ¹¹ A bladder carcinoma that has material basis in transitional cells located in the lining of the bladder.

MalaCards based summary: Bladder Urothelial Carcinoma, also known as transitional cell carcinoma of the bladder, is related to bladder cancer and papilloma. An important gene associated with Bladder Urothelial Carcinoma is TUG1 (Taurine Up-Regulated 1), and among its related pathways/superpathways are Gene expression (Transcription) and ERK Signaling. The drugs Bifidobacterium and Acidophilus have been mentioned in the context of this disorder. Affiliated tissues include lining of the bladder, lymph node and prostate, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Sources

Related Diseases for Bladder Urothelial Carcinoma

Diseases related to Bladder Urothelial Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 554)

#	Related Disease	Score	Top Affiliating Genes
1	bladder cancer	31.2	TUG1 TP53 PVT1 PIK3CA MEG3 MALAT1
2	papilloma	31.1	TP53 KRAS FGFR3 ERBB2 CDKN2A AKT1
3	vulva cancer	30.9	TP53 PIK3CA ERBB2 CDKN2A
4	schimmelpenning-feuerstein-mims syndrome	30.9	PIK3CA KRAS FGFR3
5	vulval paget's disease	30.9	ERBB2 CDKN2A
6	penile cancer	30.9	TP53 PIK3CA CDKN2A
7	adenoma	30.8	TP53 PIK3CA KRAS CTNNB1 CDKN2A AKT1
8	villous adenoma	30.8	TP53 KRAS CTNNB1
9	nevus, epidermal	30.8	PIK3CA KRAS FGFR3 AKT1
10	exanthem	30.7	KRAS ERBB2 AKT1
11	brain cancer	30.7	U2AF1 TP53 PIK3CA CTNNB1 AKT1
12	adenocarcinoma	30.7	TP53 PIK3CA MALAT1 KRAS FGFR3 ERBB2
13	ureteral benign neoplasm	30.7	TP53 FGFR3
14	plasmacytoma	30.6	PVT1 GAS5 CDKN2A AKT1
15	carcinosarcoma	30.6	TP53 PIK3CA KRAS FBXW7 ERBB2 CTNNB1
16	suppression of tumorigenicity 12	30.6	U2AF1 TP53 PIK3CA ERBB2 CTNNB1 CDKN2A
17	thyroid carcinoma	30.6	PVT1 MALAT1 HOTAIR GAS5
18	human papillomavirus infectious disease	30.6	TP53 PIK3CA ERBB2 CDKN2A AKT1
19	basal cell nevus syndrome	30.6	TP53 CTNNB1 AKT1
20	thyroid cancer, nonmedullary, 1	30.6	TP53 PVT1 MEG3 MALAT1 HOTAIR
21	rectal benign neoplasm	30.6	TP53 PIK3CA KRAS CTNNB1
22	signet ring cell adenocarcinoma	30.6	TP53 KRAS ERBB2 CTNNB1
23	li-fraumeni syndrome	30.6	U2AF1 TP53 PIK3CA KRAS ERBB2 CTNNB1
24	cervical squamous cell carcinoma	30.5	TP53 PIK3CA KRAS FBXW7 EP300 CDKN2A
25	large cell carcinoma	30.5	TP53 KRAS ERBB2
26	diffuse gastric cancer	30.5	TP53 PIK3CA KRAS ERBB2 CTNNB1
27	lynch syndrome	30.5	U2AF1 TP53 PIK3CA KRAS FBXW7 ERBB2
28	sarcoma	30.5	TP53 PIK3CA KRAS HOTAIR CTNNB1
29	colon adenocarcinoma	30.5	TP53 PIK3CA KRAS FBXW7 CTNNB1
30	low grade glioma	30.4	TP53 CDKN2A AKT1
31	mucinous adenocarcinoma	30.4	U2AF1 TP53 PIK3CA KRAS ERBB2 CTNNB1
32	peripheral nervous system disease	30.4	U2AF1 TP53 KRAS ERBB2 CTNNB1 CDKN2A
33	colorectal adenocarcinoma	30.4	TP53 PIK3CA KRAS ERBB2 CTNNB1 AKT1
34	renal cell carcinoma, papillary, 1	30.3	U2AF1 TP53 PIK3CA KRAS FGFR3 FBXW7
35	gastric adenocarcinoma	30.3	TP53 PIK3CA KRAS HOTAIR FBXW7 ERBB2
36	cholangiocarcinoma	30.3	TUG1 TP53 PIK3CA MALAT1 KRAS ERBB2
37	adrenal cortical carcinoma	30.3	TP53 PIK3CA KRAS ERBB2 CTNNB1 CDKN2A
38	head and neck cancer	30.3	U2AF1 TP53 PIK3CA KRAS GAS5 ERBB2
39	retinoblastoma	30.3	TP53 MEG3 MALAT1 HOTAIR EP300 CDKN2A
40	endocervical adenocarcinoma	30.3	U2AF1 TP53 PIK3CA FBXW7 ERBB2 EP300
41	colonic benign neoplasm	30.3	TP53 PIK3CA KRAS FBXW7 ERBB2 CTNNB1
42	melanoma	30.3	TP53 PVT1 PIK3CA MEG3 MALAT1 KRAS
43	small cell cancer of the lung	30.3	TUG1 TP53 PIK3CA MALAT1 HOTAIR CDKN2A
44	pancreatic adenocarcinoma	30.2	U2AF1 TP53 RXRA PIK3CA KRAS ERBB2
45	suppressor of tumorigenicity 3	30.2	TP53 CDKN2A
46	squamous cell carcinoma	29.9	TUG1 TP53 PIK3CA MALAT1 KRAS HOTAIR
47	breast cancer	29.9	TUG1 TP53 PVT1 PIK3CA MEG3 MALAT1
48	prostate cancer	29.8	TUG1 TP53 PVT1 PIK3CA MEG3 MALAT1
49	pancreatic cancer	29.7	TUG1 TP53 PVT1 PIK3CA MEG3 MALAT1
50	renal cell carcinoma, nonpapillary	29.6	U2AF1 TUG1 TP53 PVT1 PIK3CA MEG3

Graphical network of the top 20 diseases related to Bladder Urothelial Carcinoma:

Sources

Symptoms & Phenotypes for Bladder Urothelial Carcinoma

GenomeRNAi Phenotypes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

²⁵ (show all 27)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	10.68	KRAS PIK3CA
2	Decreased viability	GR00055-A-2	10.68	KRAS PIK3CA
3	Decreased viability	GR00055-A-3	10.68	KRAS
4	Decreased viability	GR00106-A-0	10.68	KRAS
5	Decreased viability	GR00221-A-1	10.68	AKT1 FGFR3 KRAS PIK3CA CDKN2A RXRA
6	Decreased viability	GR00221-A-2	10.68	AKT1 EP300 FGFR3 KRAS PIK3CA
7	Decreased viability	GR00221-A-3	10.68	AKT1 FGFR3 CDKN2A
8	Decreased viability	GR00221-A-4	10.68	AKT1 PIK3CA CDKN2A
9	Decreased viability	GR00249-S	10.68	AKT1 FGFR3 RXRA
10	Decreased viability	GR00301-A	10.68	KRAS
11	Decreased viability	GR00381-A-1	10.68	KRAS RXRA
12	Decreased viability	GR00402-S-2	10.68	PIK3CA
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	9.77	KRAS
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-121	9.77	FBXW7
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-122	9.77	FBXW7
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-183	9.77	FBXW7
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-213	9.77	AKT1
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-22	9.77	KRAS
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	9.77	CTNNB1
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-52	9.77	FBXW7
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-60	9.77	AKT1 PIK3CA
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	9.77	KRAS
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-70	9.77	AKT1
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	9.77	AKT1
25	Increased cell migration	GR00055-A-1	9.16	CTNNB1
26	Increased cell migration	GR00055-A-3	9.16	CTNNB1
27	Increased CDKN1A mRNA expression	GR00389-S-1	8.32	EP300

MGI Mouse Phenotypes related to Bladder Urothelial Carcinoma:

⁴⁵ (show all 22)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	10.41	AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
2	homeostasis/metabolism	MP:0005376	10.41	AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
3	nervous system	MP:0003631	10.39	AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
4	normal	MP:0002873	10.37	AKT1 CREBBP CTNNB1 EP300 ERBB2 FBXW7
5	cellular	MP:0005384	10.33	AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
6	muscle	MP:0005369	10.31	AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
7	embryo	MP:0005380	10.29	AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
8	endocrine/exocrine gland	MP:0005379	10.26	AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
9	no phenotypic analysis	MP:0003012	10.24	CDKN2A CTNNB1 FGFR3 HOTAIR KRAS MALAT1
10	digestive/alimentary	MP:0005381	10.24	CDKN2A CREBBP CTNNB1 EP300 ERBB2 FBXW7
11	immune system	MP:0005387	10.22	AKT1 CDKN2A CREBBP CTNNB1 EP300 FBXW7
12	liver/biliary system	MP:0005370	10.21	AKT1 CDKN2A CREBBP CTNNB1 FBXW7 KRAS
13	cardiovascular system	MP:0005385	10.21	AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
14	limbs/digits/tail	MP:0005371	10.15	CREBBP CTNNB1 ERBB2 FGFR3 HOTAIR KRAS
15	respiratory system	MP:0005388	10.15	AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
16	craniofacial	MP:0005382	10.13	CREBBP CTNNB1 EP300 ERBB2 FBXW7 FGFR3
17	skeleton	MP:0005390	10.1	AKT1 CDKN2A CREBBP CTNNB1 ERBB2 FGFR3
18	pigmentation	MP:0001186	10.08	CDKN2A CTNNB1 KRAS RXRA TP53 U2AF1
19	vision/eye	MP:0005391	9.96	CDKN2A CTNNB1 EP300 FBXW7 FGFR3 KRAS
20	hematopoietic system	MP:0005397	9.93	AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
21	mortality/aging	MP:0010768	9.83	AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
22	integument	MP:0010771	9.4	AKT1 CDKN2A CREBBP CTNNB1 ERBB2 FBXW7

Sources

Drugs & Therapeutics for Bladder Urothelial Carcinoma

Drugs for Bladder Urothelial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Bifidobacterium

Phase 4

Acidophilus

Phase 4

Aminolevulinic acid

Approved

Phase 3

106-60-5

137

Bevacizumab

Approved, Investigational

Phase 3

216974-75-3

135329020

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Docetaxel

Approved, Investigational

Phase 3

114977-28-5

148124

Nivolumab

Approved

Phase 3

946414-94-4

Atezolizumab

Approved, Investigational

Phase 3

1380723-44-3

Fluorouracil

Approved

Phase 3

51-21-8

3385

BCG vaccine

Approved, Investigational

Phase 3

Mitomycin

Approved

Phase 3

50-07-7

5746

Gefitinib

Approved, Investigational

Phase 3

184475-35-2

123631

Ciprofloxacin

Approved, Investigational

Phase 3

85721-33-1, 93107-08-5

2764

Cephalexin

Approved, Investigational, Vet_approved

Phase 3

15686-71-2

27447

Laevulinic Acid

Experimental

Phase 3

123-76-2

11579

Angiogenesis Inhibitors

Phase 3

Photosensitizing Agents

Phase 3

Vitamins

Phase 3

Mitogens

Phase 3

Endothelial Growth Factors

Phase 3

Pharmaceutical Solutions

Phase 3

Immunologic Factors

Phase 3

Vaccines

Phase 3

Protein Kinase Inhibitors

Phase 3

Anti-Bacterial Agents

Phase 3

Antibiotics, Antitubercular

Phase 3

Adjuvants, Immunologic

Phase 3

Fluoroquinolones

Phase 3

Cytochrome P-450 Enzyme Inhibitors

Phase 3

Aflibercept

Approved

Phase 2

862111-32-8

124490314

Bortezomib

Approved, Investigational

Phase 2

179324-69-7

387447 93860

Arsenic trioxide

Approved, Investigational

Phase 2

1327-53-3

518740

Ramucirumab

Approved, Investigational

Phase 2

947687-13-0

Epirubicin

Approved

Phase 2

56420-45-2

41867

Erlotinib

Approved, Investigational

Phase 2

183319-69-9, 183321-74-6

176870

Altretamine

Approved

Phase 2

645-05-6

2123

Propranolol

Approved, Investigational

Phase 2

318-98-9, 525-66-6

62882 4946

Tremelimumab

Approved, Investigational

Phase 2

745013-59-6

Ipilimumab

Approved

Phase 2

477202-00-9

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

Daunorubicin

Approved

Phase 2

20830-81-3

30323

Pemetrexed

Approved, Investigational

Phase 2

150399-23-8, 137281-23-3

60843 446556 135565230

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Dimethyl sulfoxide

Approved, Vet_approved

Phase 1, Phase 2

67-68-5

679

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Gemcitabine

Approved

Phase 2

95058-81-4, 122111-03-9

60750

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239

Trastuzumab

Approved, Investigational

Phase 2

180288-69-1

Interventional clinical trials:

(show top 50) (show all 157)

#	Name	Status	NCT ID	Phase	Drugs
1	An Open Label, Randomized Control Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma	Recruiting	NCT05220124	Phase 4	Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)
2	A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma	Not yet recruiting	NCT05488353	Phase 4	Disitamab Vedotin for Injection,Penpulimab Injection
3	Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study	Unknown status	NCT00146276	Phase 3	gemcitabine
4	A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine	Completed	NCT02101931	Phase 3	Amino levulinic Acid
5	Randomized Phase III Trial Comparing Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients With pT3-pT4, and/or N+M0 Transitional Cell Carcinoma (TCC) of the Bladder	Completed	NCT00028756	Phase 3	doxorubicin hydrochloride;gemcitabine hydrochloride;vinblastine sulfate;methotrexate;cisplatin
6	Randomised Trial of Selective Bladder Preservation Against Radical Excision (Cystectomy) in Muscle Invasive T2/T3 Transitional Cell Carcinoma of the Bladder - Feasibility Study	Completed	NCT00867347	Phase 3
7	A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse	Completed	NCT00003701	Phase 3	carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
8	Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder	Completed	NCT00014534	Phase 3	cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride
9	Megadose Vitamins as Chemoprevention of Transitional Cell Carcinoma of the Bladder	Completed	NCT00003623	Phase 3
10	A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma	Completed	NCT00942331	Phase 3	Cisplatin;Gemcitabine Hydrochloride
11	A Phase III Randomized Trial of Eribulin (NSC #707389) With or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy	Recruiting	NCT04579224	Phase 3	Docetaxel;Eribulin Mesylate;Gemcitabine Hydrochloride;Paclitaxel
12	Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (IMAGINE)	Recruiting	NCT04637594	Phase 3	Pembrolizumab;Nivolumab;Atezolizumab;Durvalumab;Avelumab
13	MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer	Recruiting	NCT05092958	Phase 3	Avelumab;Cabozantinib S-malate
14	Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer	Recruiting	NCT03775265	Phase 3	Atezolizumab;Cisplatin;Fluorouracil;Gemcitabine;Mitomycin
15	Neoadjuvant Chemotherapy in Upper Tract Urothelial Cancer: A Multicentre, Feasibility Pilot Trial	Recruiting	NCT04574960	Phase 3	Gemcitabine;Cisplatin;Carboplatin
16	S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer	Active, not recruiting	NCT03091660	Phase 3
17	Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation	Active, not recruiting	NCT03244384	Phase 3
18	A Multicenter, Randomized, Double-blind, Controlled Phase III Non-inferiority Study Assessing Efficacy and Safety of VERITY-BCG in Management of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) in BCG-naïve Patients.	Not yet recruiting	NCT05037279	Phase 3	Bacillus Calmette-Guerin: Strain Russian BCG-I;Bacillus Calmette-Guerin: Strain TICE
19	A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB)	Terminated	NCT00384891	Phase 3	Bacillus Calmette-Guérin
20	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder	Terminated	NCT00191477	Phase 3	Gemcitabine;Placebo
21	A Phase III Study of IRESSA in Combination With Intravesical BCG Versus Intravesical BCG Alone in High Risk Superficial Transitional Cell Carcinoma of the Bladder	Terminated	NCT00352079	Phase 3	gefitinib
22	The Effect of Fluoroquinolones on the Disease-Free Interval in Patients With Stage Ta Transitional Cell Carcinoma of the Bladder	Terminated	NCT00003824	Phase 3	cephalexin;Ciprofloxacin
23	A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS)	Unknown status	NCT02662309	Phase 2	MPDL3280A
24	A Phase II Study of Neoadjuvant Cisplatin and Gemcitabine Plus Sorafenib for Patients With Transitional-Cell Carcinoma of the Bladder	Unknown status	NCT01222676	Phase 2	cisplatin;gemcitabine hydrochloride;sorafenib tosylate
25	A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer	Unknown status	NCT01326871	Phase 1, Phase 2	Cisplatin;Gemcitabine
26	A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Injection in Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma	Unknown status	NCT03113266	Phase 2
27	A Phase II Safety and Efficacy Study With the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients With Metastatic Urothelial Cancer	Completed	NCT00471536	Phase 2	pazopanib hydrochloride
28	A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency	Completed	NCT00478361	Phase 2	Gemcitabine hydrochloride;Paclitaxel;Doxorubicin hydrochloride;Pegfilgrastim
29	A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer	Completed	NCT03081858	Phase 1, Phase 2	TSD-001
30	A Phase II Study of VEGF Trap (NSC 724770) in Patients With Recurrent or Metastatic Transitional Carcinoma of the Urothelium	Completed	NCT00407485	Phase 2
31	Phase II Trial of PS-341 (Bortezomib) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma	Completed	NCT00072150	Phase 2	bortezomib
32	Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer	Completed	NCT00005831	Phase 2	paclitaxel;carboplatin;gemcitabine hydrochloride
33	A Phase II Study of BAY 43-9006 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter and Renal Pelvis)	Completed	NCT00112671	Phase 2	sorafenib tosylate
34	A Phase II Study Of Epothilone B Analogue BMS-247550 (NSC #710428) q21 Days In Advanced Carcinoma Of The Urothelium	Completed	NCT00021099	Phase 2	ixabepilone
35	A PHASE II STUDY OF ARSENIC TRIOXIDE (NSC #706363, IND #57974) IN UROTHELIAL CANCER	Completed	NCT00009867	Phase 2	arsenic trioxide
36	Prospective Phase II Randomized Trial of Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer	Completed	NCT01824329	Phase 2
37	Multicenter Randomized Phase 2 Trial of Gemcitabine - Platinum With or Without Trastuzumab in Advanced or Metastatic Urothelial Carcinoma With HER2 Overexpression	Completed	NCT01828736	Phase 2	Gemcitabine;Carboplatin;Cisplatin
38	A Phase 2 Study of the Aurora Kinase A Inhibitor Alisertib (MLN8237) in Patients With Relapsed or Refractory Transitional-cell Carcinoma of the Bladder and Urothelial Tract	Completed	NCT02109328	Phase 2	Alisertib;Paclitaxel;Placebo
39	Phase II Single Arm, Open Label, Single Institution Study of Neoadjuvant Sunitinib (SUTENT) in Patients With Muscle-Invasive Locally Advanced Transitional Cell Carcinoma of the Bladder	Completed	NCT00526656	Phase 2	sunitinib malate
40	Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Transitional Cell Carcinoma of the Bladder	Completed	NCT00136175	Phase 2	Paclitaxel;Carboplatin;Gemcitabine
41	Phase II Evaluation of Robotic-assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder	Completed	NCT00963859	Phase 2
42	An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy	Completed	NCT01282463	Phase 2	Docetaxel
43	Phase II Study of the Fully Human Monoclonal Antibody Against Transforming Growth Factor-beta (TGFβ) Receptor ALK1 (PF-03446962) in Relapsed or Refractory Urothelial Cancer (UC) Failing First-line Treatment.	Completed	NCT01620970	Phase 2	PF03446962
44	Clinical Study of Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder After Surgical Management	Completed	NCT00343356	Phase 2	Trement
45	A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder	Completed	NCT00047216	Phase 2	tipifarnib
46	Randomized Phase II Study Assessing the Combination of Vinflunine With Gemcitabine and Vinflunine With Carboplatin in Patients Ineligible to Cisplatin With Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium	Completed	NCT01599013	Phase 2	Vinflunine, Gemcitabine;Vinflunine, Carboplatin
47	Acupuncture vs. Standard of Care for Induction Intravesical BCG-Related Adverse Events in High-Risk Non-Muscle Invasive Bladder Cancer	Completed	NCT04496219	Phase 2
48	Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder	Completed	NCT02178241	Phase 2	Eribulin Mesylate;Gemcitabine Hydrochloride
49	A Phase II Exploratory Study of Pre-Operative Treatment With Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy	Completed	NCT00749892	Phase 2	Erlotinib Hydrochloride
50	A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer	Completed	NCT00238420	Phase 1, Phase 2	Paclitaxel

Search NIH Clinical Center for Bladder Urothelial Carcinoma

Sources

Genetic Tests for Bladder Urothelial Carcinoma

Genetic tests related to Bladder Urothelial Carcinoma:

#	Genetic test	Affiliating Genes
1	Transitional Cell Carcinoma of the Bladder ²⁸

Sources

Anatomical Context for Bladder Urothelial Carcinoma

Organs/tissues related to Bladder Urothelial Carcinoma:

FMA: Lining Of The Bladder

MalaCards : Lymph Node, Prostate, Lung, Endothelial, Liver, Myeloid, Kidney

Sources

Publications for Bladder Urothelial Carcinoma

Articles related to Bladder Urothelial Carcinoma:

(show top 50) (show all 3890)

#	Title	Authors	PMID	Year
1	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. ⁵	Chang MT...Taylor BS	26619011	2016
2	Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. ⁵	Wagle N...Rosenberg JE	24625776	2014
3	Immunohistochemical positive stained p53 protein in bladder transitional cell carcinoma. ⁵³ ⁶²	Halimi M...Nezami N	19332900	2009
4	Identification of survivin, an inhibitor of apoptosis, in canine urinary bladder transitional cell carcinoma. ⁵³ ⁶²	Rankin WV...Green JA	19178674	2008
5	E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma. ⁵³ ⁶²	Shi B...Xu Z	18931551	2008
6	Shikonin-induced apoptosis involves caspase-3 activity in a human bladder cancer cell line (T24). ⁵³ ⁶²	Yeh CC...Yang JS	18210748	2007
7	Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. ⁵³ ⁶²	Shariat SF...Lotan Y	17311310	2007
8	Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. ⁵³ ⁶²	Esuvaranathan K...Teh M	17311305	2007
9	Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. ⁵³ ⁶²	Shariat SF...Lotan Y	17222615	2007
10	Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder. ⁵³ ⁶²	Buscarini M...Bochner B	17293658	2007
11	Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. ⁵³ ⁶²	Zu X...Qi L	17034609	2006
12	[Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof]. ⁵³ ⁶²	Zhou JT...Na YQ	17064593	2006
13	p53 protein in serum and urine samples of patients with bladder transitional cell carcinoma and its overexpression in tumoral tissue. ⁵³ ⁶²	Darabi M...Arab D	17559044	2006
14	Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. ⁵³ ⁶²	Matsumoto K...Lerner SP	16040097	2005
15	Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. ⁵³ ⁶²	Suzuki K...Tokue A	15733109	2005
16	Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. ⁵³ ⁶²	Tyagi A...Agarwal R	15117815	2004
17	Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. ⁵³ ⁶²	Chatterjee SJ...Cote RJ	14981105	2004
18	p53 Gene mutations in superficial bladder cancer. ⁵³ ⁶²	Lorenzo Romero JG...Virseda Rodriguez JA	15539839	2004
19	[Expression of cyclooxygenase in bladder transitional cell carcinoma]. ⁵³ ⁶²	Wang KJ...Yang YR	14981815	2004
20	[Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67]. ⁵³ ⁶²	Rodriguez Alonso A...Nogueira March JL	12731328	2003
21	Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. ⁵³ ⁶²	Chan MW...To KF	11839665	2002
22	The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome. ⁵³ ⁶²	Babjuk M...Povysil C	14577491	2002
23	Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. ⁵³ ⁶²	Tiguert R...Sarkar FH	11696726	2001
24	Expression of pS2 protein and its relation with the Ki-67 proliferative indices and tumor recurrence in superficial bladder carcinomas. ⁵³ ⁶²	Sagol O...Kirkali Z	11528193	2001
25	E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. ⁵³ ⁶²	Byrne RR...Lerner SP	11342899	2001
26	Expression of multidrug-associated protein, P-glycoprotein, P53 and Bcl-2 proteins in bladder cancer and clinical implication. ⁵³ ⁶²	Chen Z...Zhang Y	11523249	2001
27	[The study on relation of human papillomavirus and P53 expression with bladder transitional cell carcinoma]. ⁵³ ⁶²	Chen T...Cao H	11471022	2000
28	The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. ⁵³ ⁶²	Wu TT...Huang JK	10687971	2000
29	Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. ⁵³ ⁶²	Chang S...Kim Y	10699635	2000
30	Correlative expression of glutathione S-transferase-pi and multidrug resistance associated protein in bladder transitional cell carcinoma. ⁵³ ⁶²	Yang W...Du G	12840920	2000
31	Primary seminal vesicle carcinoma: an immunohistochemical analysis of four cases. ⁵³ ⁶²	Ormsby AH...Goldblum JR	10658909	2000
32	A novel tumor-specific gene therapy for bladder cancer. ⁵³ ⁶²	Pan CX...Koeneman KS	10532707	1999
33	[Immunohistochemical study of p53 and Ki-67 antigen expression in bladder carcinoma]. ⁵³ ⁶²	Yuge F...Takimoto Y	10466059	1999
34	Cytokeratin 20: a new marker for early detection of bladder cell carcinoma? ⁵³ ⁶²	Buchumensky V...Nissenkorn I	9817302	1998
35	The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy. ⁵³ ⁶²	Tzai TS...Tong YC	9891547	1998
36	Expression of bcl-2 and bcl-X in bladder cancer. ⁵³ ⁶²	Kirsh EJ...Stadler WM	9507882	1998
37	Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guérin treatment. ⁵³ ⁶²	Ick K...Fan K	9111623	1997
38	p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage. ⁵³ ⁶²	Skopelitou A...Agnantis NJ	9187909	1997
39	Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. ⁵³ ⁶²	Ross JS...Figge J	8871928	1996
40	[Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder]. ⁵³ ⁶²	Yu D...Liang Z	9275651	1996
41	[Ectopic production of HCG beta by bladder carcinoma in vitro and in vivo]. ⁵³ ⁶²	Morisue K...Nishimura R	8709440	1996
42	Expression of p53 product in Chinese human bladder carcinoma. ⁵³ ⁶²	Ye DW...Ma YJ	7688167	1993
43	MiRNA-139-3p inhibits malignant progression in urothelial carcinoma of the bladder via targeting KIF18B and inactivating Wnt/beta-catenin pathway. ⁶²	Zhang W...Liu Z	36441170	2023
44	Incidental findings on staging CT for rectal cancer: Frequency, clinical significance and outcomes. ⁶²	Tang YZ...Alabousi A	36356382	2023
45	Quantitative proteomics identifies TUBB6 as a biomarker of muscle-invasion and poor prognosis in bladder cancer. ⁶²	Kim B...Ryu HS	36054443	2023
46	Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial. ⁶²	Basile G...Necchi A	36190522	2022
47	Epigenetic regulation of MIR145 core promoter controls miR-143/145 cluster in bladder cancer progression and treatment outcome. ⁶²	Pilala KM...Avgeris M	36320325	2022
48	["Surgery only" is not enough: potential of multimodal therapy in urothelial bladder carcinoma]. ⁶²	Schmid SC...Rodel C	36352266	2022
49	Fibroblast activation protein (FAP) expression in CK5/6 expressed (Basal subtype) & CK20 expressed (Luminal subtype) urothelial bladder carcinoma: an immunohistochemical study. ⁶²	Hemida AS...Al Sharaky DR	35787739	2022
50	The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk. ⁶²	Yang Y...Yang H	36451132	2022

Sources

Genes for Bladder Urothelial Carcinoma

Genes related to Bladder Urothelial Carcinoma (0 elite genes):

(show top 50) (show all 55)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	TUG1	Taurine Up-Regulated 1	Protein Coding	155.43	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	22961206 29179467
2	GAS5	Growth Arrest Specific 5	RNA Gene	155.33	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28060759
3	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	155.25	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	26781446 28060759
4	PVT1	Pvt1 Oncogene	RNA Gene	155.01	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	28969069
5	CRNDE	Colorectal Neoplasia Differentially Expressed	RNA Gene	153.54	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28060759
6	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	153.46	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	23153939 28060759
7	MEG3	Maternally Expressed 3	RNA Gene	153.04	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28060759
8	TP53	Tumor Protein P53	Protein Coding	55.11	Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	26619011 11471022 9275651 (more) 10687971 9891547 15539839 17559044 14981105 11696726 10606186 17222615 17311305 19332900 9507882 14577491 9187909 9816267 12706858 9490274 11523249 7677935 12731328 10532707 9111623 7537927 7688167 16343743 10466059
9	FGFR3	Fibroblast Growth Factor Receptor 3	Protein Coding	47.37	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)	26619011
10	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	45.79	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)	26619011
11	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	37.77	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)	26619011
12	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	37.34	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)	26619011
13	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	37.15	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)	26619011
14	EP300	E1A Binding Protein P300	Protein Coding	36.47	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)	26619011
15	FBXW7	F-Box And WD Repeat Domain Containing 7	Protein Coding	36.14	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)	26619011
16	CREBBP	CREB Binding Protein	Protein Coding	36.08	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)	26619011
17	RXRA	Retinoid X Receptor Alpha	Protein Coding	35.2	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)	26619011
18	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	33.05	Likely pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴	26619011
19	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	31.15	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
20	CTNNB1	Catenin Beta 1	Protein Coding	30.96	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
21	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	30.91	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
22	PTEN	Phosphatase And Tensin Homolog	Protein Coding	30.88	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
23	IDH1	Isocitrate Dehydrogenase (NADP(+)) 1	Protein Coding	29.98	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
24	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	29.9	Likely pathogenic ⁵ DISEASES inferred ¹⁴	24625776
25	FGFR1	Fibroblast Growth Factor Receptor 1	Protein Coding	29.76	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
26	ERBB3	Erb-B2 Receptor Tyrosine Kinase 3	Protein Coding	29.56	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
27	MAP2K1	Mitogen-Activated Protein Kinase Kinase 1	Protein Coding	29.38	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
28	MAPK1	Mitogen-Activated Protein Kinase 1	Protein Coding	29.16	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
29	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	29.16	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
30	NFE2L2	NFE2 Like BZIP Transcription Factor 2	Protein Coding	29.04	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
31	RHEB	Ras Homolog, MTORC1 Binding	Protein Coding	28.19	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
32	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	28.13	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
33	SF3B1	Splicing Factor 3b Subunit 1	Protein Coding	28.02	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
34	CNOT9	CCR4-NOT Transcription Complex Subunit 9	Protein Coding	25	Likely pathogenic ⁵	26619011
35	LRRC56	Leucine Rich Repeat Containing 56	Protein Coding	25	Likely pathogenic ⁵	26619011
36	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	19.58	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
37	RB1	RB Transcriptional Corepressor 1	Protein Coding	19.49	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
38	ELF3	E74 Like ETS Transcription Factor 3	Protein Coding	18.85	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
39	CDH1	Cadherin 1	Protein Coding	12.36	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11342899 16142373 18931551 (more) 11839665 8871928 11205306
40	ARID1A	AT-Rich Interaction Domain 1A	Protein Coding	12.13	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
41	KDM6A	Lysine Demethylase 6A	Protein Coding	12.05	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
42	KMT2D	Lysine Methyltransferase 2D	Protein Coding	11.97	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
43	METTL3	Methyltransferase 3, N6-Adenosine-Methyltransferase Complex Catalytic Subunit	Protein Coding	11.67	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
44	ATM	ATM Serine/Threonine Kinase	Protein Coding	11.6	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
45	KMT2C	Lysine Methyltransferase 2C	Protein Coding	11.56	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
46	STAG2	Stromal Antigen 2	Protein Coding	11.44	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
47	MKI67	Marker Of Proliferation Ki-67	Protein Coding	11.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9490274 10466059 12731328 (more) 11528193
48	MUC16	Mucin 16, Cell Surface Associated	Protein Coding	11.07	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
49	KMT2A	Lysine Methyltransferase 2A	Protein Coding	10.72	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
50	KRT20	Keratin 20	Protein Coding	10.71	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9817302 10658909

Sources

Variations for Bladder Urothelial Carcinoma

ClinVar genetic disease variations for Bladder Urothelial Carcinoma:

⁵ (show top 50) (show all 276)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	RXRA	NM_002957.6(RXRA):c.1280C>T (p.Ser427Phe)	SNV	Likely Pathogenic	376528	rs1057519958	GRCh37: 9:137328351-137328351 GRCh38: 9:134436505-134436505
2	MAP2K1	NM_002755.4(MAP2K1):c.371C>A (p.Pro124Gln)	SNV	Likely Pathogenic	40743	rs397516792	GRCh37: 15:66729163-66729163 GRCh38: 15:66436825-66436825
3	FBXW7	NM_001349798.2(FBXW7):c.1973G>A (p.Arg658Gln)	SNV	Likely Pathogenic	376427	rs759610249	GRCh37: 4:153244184-153244184 GRCh38: 4:152323032-152323032
4	RXRA	NM_002957.6(RXRA):c.1280C>A (p.Ser427Tyr)	SNV	Likely Pathogenic	376529	rs1057519958	GRCh37: 9:137328351-137328351 GRCh38: 9:134436505-134436505
5	MTOR	NM_004958.4(MTOR):c.7255G>A (p.Glu2419Lys)	SNV	Likely Pathogenic	156709	rs587777900	GRCh37: 1:11174420-11174420 GRCh38: 1:11114363-11114363
6	PIK3CA	NM_006218.4(PIK3CA):c.316G>C (p.Gly106Arg)	SNV	Likely Pathogenic	376480	rs1057519931	GRCh37: 3:178916929-178916929 GRCh38: 3:179199141-179199141
7	MTOR	NM_004958.4(MTOR):c.6040G>A (p.Glu2014Lys)	SNV	Likely Pathogenic	376131	rs1057519780	GRCh37: 1:11187857-11187857 GRCh38: 1:11127800-11127800
8	RHEB	NM_005614.4(RHEB):c.103T>A (p.Tyr35Asn)	SNV	Likely Pathogenic	376515	rs1057519949	GRCh37: 7:151188050-151188050 GRCh38: 7:151490964-151490964
9	RHEB	NM_005614.4(RHEB):c.104A>G (p.Tyr35Cys)	SNV	Likely Pathogenic	376516	rs1057519950	GRCh37: 7:151188049-151188049 GRCh38: 7:151490963-151490963
10	SF3B1	NM_012433.4(SF3B1):c.1874G>A (p.Arg625His)	SNV	Likely Pathogenic	376534	rs1057519961	GRCh37: 2:198267483-198267483 GRCh38: 2:197402759-197402759
11	SF3B1	NM_012433.4(SF3B1):c.1873C>T (p.Arg625Cys)	SNV	Likely Pathogenic	376535	rs775623976	GRCh37: 2:198267484-198267484 GRCh38: 2:197402760-197402760
12	PIK3CA	NM_006218.4(PIK3CA):c.317G>T (p.Gly106Val)	SNV	Likely Pathogenic	376479	rs1057519930	GRCh37: 3:178916930-178916930 GRCh38: 3:179199142-179199142
13	HRAS, LRRC56	NM_005343.4(HRAS):c.182A>C (p.Gln61Pro)	SNV	Likely Pathogenic	376322	rs121913233	GRCh37: 11:533874-533874 GRCh38: 11:533874-533874
14	U2AF1	NM_006758.3(U2AF1):c.101C>T (p.Ser34Phe)	SNV	Likely Pathogenic	376025	rs371769427	GRCh37: 21:44524456-44524456 GRCh38: 21:43104346-43104346
15	ERBB2	NM_004448.4(ERBB2):c.2305G>T (p.Asp769Tyr)	SNV	Likely Pathogenic	375992	rs121913468	GRCh37: 17:37880261-37880261 GRCh38: 17:39724008-39724008
16	PIK3CA	NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly)	SNV	Likely Pathogenic	13656	rs121913274	GRCh37: 3:178936092-178936092 GRCh38: 3:179218304-179218304
17	FBXW7	NM_001349798.2(FBXW7):c.1513C>A (p.Arg505Ser)	SNV	Likely Pathogenic	376426	rs149680468	GRCh37: 4:153247289-153247289 GRCh38: 4:152326137-152326137
18	ERBB2	NM_004448.4(ERBB2):c.2033G>A (p.Arg678Gln)	SNV	Likely Pathogenic	376344	rs1057519862	GRCh37: 17:37879658-37879658 GRCh38: 17:39723405-39723405
19	PIK3CA	NM_006218.4(PIK3CA):c.1625A>C (p.Glu542Ala)	SNV	Likely Pathogenic	376473	rs1057519927	GRCh37: 3:178936083-178936083 GRCh38: 3:179218295-179218295
20	NFE2L2	NM_006164.5(NFE2L2):c.235G>C (p.Glu79Gln)	SNV	Likely Pathogenic	376465	rs1057519922	GRCh37: 2:178098810-178098810 GRCh38: 2:177234082-177234082
21	ERBB3	NM_001982.4(ERBB3):c.310G>T (p.Val104Leu)	SNV	Likely Pathogenic	376411	rs1057519893	GRCh37: 12:56478854-56478854 GRCh38: 12:56085070-56085070
22	CNOT9	NM_005444.3(CNOT9):c.259T>C (p.Ser87Pro)	SNV	Likely Pathogenic	376526	rs1057519956	GRCh37: 2:219447748-219447748 GRCh38: 2:218583025-218583025
23	NFE2L2	NM_006164.5(NFE2L2):c.86A>G (p.Asp29Gly)	SNV	Likely Pathogenic	376464	rs1057519921	GRCh37: 2:178098959-178098959 GRCh38: 2:177234231-177234231
24	HRAS, LRRC56	NM_005343.4(HRAS):c.183G>T (p.Gln61His)	SNV	Likely Pathogenic	376318	rs121913496	GRCh37: 11:533873-533873 GRCh38: 11:533873-533873
25	FBXW7	NM_001349798.2(FBXW7):c.1436G>A (p.Arg479Gln)	SNV	Likely Pathogenic	376419	rs866987936	GRCh37: 4:153247366-153247366 GRCh38: 4:152326214-152326214
26	ERBB2	NM_004448.4(ERBB2):c.929C>T (p.Ser310Phe)	SNV	Likely Pathogenic	376189	rs1057519816	GRCh37: 17:37868208-37868208 GRCh38: 17:39711955-39711955
27	CTNNB1	NM_001904.4(CTNNB1):c.134C>T (p.Ser45Phe)	SNV	Likely Pathogenic	17588	rs121913409	GRCh37: 3:41266137-41266137 GRCh38: 3:41224646-41224646
28	FBXW7	NM_001349798.2(FBXW7):c.1514G>A (p.Arg505His)	SNV	Likely Pathogenic	376425	rs1057519896	GRCh37: 4:153247288-153247288 GRCh38: 4:152326136-152326136
29	U2AF1	NM_006758.3(U2AF1):c.101C>A (p.Ser34Tyr)	SNV	Likely Pathogenic	376026	rs371769427	GRCh37: 21:44524456-44524456 GRCh38: 21:43104346-43104346
30	NFE2L2	NM_006164.5(NFE2L2):c.85G>A (p.Asp29Asn)	SNV	Likely Pathogenic	376463	rs1057519920	GRCh37: 2:178098960-178098960 GRCh38: 2:177234232-177234232
31	ERBB3	NM_001982.4(ERBB3):c.889G>T (p.Asp297Tyr)	SNV	Likely Pathogenic	376407	rs1057519891	GRCh37: 12:56482341-56482341 GRCh38: 12:56088557-56088557
32	PIK3CA	NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln)	SNV	Likely Pathogenic	375896	rs104886003	GRCh37: 3:178936091-178936091 GRCh38: 3:179218303-179218303
33	NFE2L2	NM_006164.5(NFE2L2):c.85G>T (p.Asp29Tyr)	SNV	Likely Pathogenic	376462	rs1057519920	GRCh37: 2:178098960-178098960 GRCh38: 2:177234232-177234232
34	PIK3CA	NM_006218.4(PIK3CA):c.3128T>C (p.Met1043Thr)	SNV	Likely Pathogenic	376486	rs1057519937	GRCh37: 3:178952073-178952073 GRCh38: 3:179234285-179234285
35	NFE2L2	NM_006164.5(NFE2L2):c.237G>T (p.Glu79Asp)	SNV	Likely Pathogenic	376468	rs1057519924	GRCh37: 2:178098808-178098808 GRCh38: 2:177234080-177234080
36	CNOT9	NM_005444.3(CNOT9):c.260C>G (p.Ser87Cys)	SNV	Likely Pathogenic	376527	rs1057519957	GRCh37: 2:219447749-219447749 GRCh38: 2:218583026-218583026
37	ERBB2	NM_004448.4(ERBB2):c.2263_2264delinsCC (p.Leu755Pro)	INDEL	Likely Pathogenic	13877	rs121913469	GRCh37: 17:37880219-37880220 GRCh38: 17:39723966-39723967
38	MAP2K1	NM_002755.4(MAP2K1):c.370C>T (p.Pro124Ser)	SNV	Likely Pathogenic	375981	rs1057519732	GRCh37: 15:66729162-66729162 GRCh38: 15:66436824-66436824
39	NFE2L2	NM_006164.5(NFE2L2):c.85G>C (p.Asp29His)	SNV	Likely Pathogenic	376461	rs1057519920	GRCh37: 2:178098960-178098960 GRCh38: 2:177234232-177234232
40	FBXW7	NM_001349798.2(FBXW7):c.1513C>T (p.Arg505Cys)	SNV	Likely Pathogenic	69961	rs149680468	GRCh37: 4:153247289-153247289 GRCh38: 4:152326137-152326137
41	ERBB3	NM_001982.4(ERBB3):c.890A>T (p.Asp297Val)	SNV	Likely Pathogenic	376408	rs1057519892	GRCh37: 12:56482342-56482342 GRCh38: 12:56088558-56088558
42	PIK3CA	NM_006218.4(PIK3CA):c.1625A>T (p.Glu542Val)	SNV	Likely Pathogenic	376474	rs1057519927	GRCh37: 3:178936083-178936083 GRCh38: 3:179218295-179218295
43	HRAS, LRRC56	NM_005343.4(HRAS):c.37G>A (p.Gly13Ser)	SNV	Likely Pathogenic	376323	rs104894228	GRCh37: 11:534286-534286 GRCh38: 11:534286-534286
44	SF3B1	NM_012433.4(SF3B1):c.1873C>G (p.Arg625Gly)	SNV	Likely Pathogenic	376536	rs775623976	GRCh37: 2:198267484-198267484 GRCh38: 2:197402760-197402760
45	CDKN2A	NM_000077.5(CDKN2A):c.247C>G (p.His83Asp)	SNV	Likely Pathogenic	376380	rs121913385	GRCh37: 9:21971111-21971111 GRCh38: 9:21971112-21971112
46	BRAF	NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg)	SNV	Likely Pathogenic	13970	rs121913357	GRCh37: 7:140481403-140481403 GRCh38: 7:140781603-140781603
47	ERBB2	NM_004448.4(ERBB2):c.2264T>C (p.Leu755Ser)	SNV	Likely Pathogenic	376035	rs121913470	GRCh37: 17:37880220-37880220 GRCh38: 17:39723967-39723967
48	ERBB2	NM_004448.4(ERBB2):c.2305G>A (p.Asp769Asn)	SNV	Likely Pathogenic	376403	rs121913468	GRCh37: 17:37880261-37880261 GRCh38: 17:39724008-39724008
49	HRAS, LRRC56	NM_005343.4(HRAS):c.182A>T (p.Gln61Leu)	SNV	Likely Pathogenic	376033	rs121913233	GRCh37: 11:533874-533874 GRCh38: 11:533874-533874
50	PIK3CA	NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)	SNV	Likely Pathogenic	13659	rs121913274	GRCh37: 3:178936092-178936092 GRCh38: 3:179218304-179218304

Sources

Expression for Bladder Urothelial Carcinoma

Search GEO for disease gene expression data for Bladder Urothelial Carcinoma.

Sources

Pathways for Bladder Urothelial Carcinoma

Pathways related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 96)

#	Super pathways	Score	Top Affiliating Genes
1	Gene expression (Transcription) ⁶⁶ Show member pathways Generic Transcription Pathway ⁶⁶ RNA Polymerase II Transcription ⁶⁶	14.12	AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.86	TP53 KRAS FGFR3 ERBB2 EP300 CTNNB1
3	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.82	TP53 PIK3CA KRAS FGFR3 FBXW7 ERBB2
4	Signal Transduction ⁶⁶	13.78	TP53 RXRA PIK3CA KRAS FGFR3 FBXW7
5	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.75	TP53 KRAS FGFR3 ERBB2 EP300 CREBBP
6	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.68	TP53 RXRA KRAS FGFR3 ERBB2 EP300
7	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.58	AKT1 CREBBP EP300 ERBB2 FGFR3 KRAS
8	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.4	TP53 PIK3CA KRAS FGFR3 ERBB2 EP300
9	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.39	AKT1 CREBBP CTNNB1 EP300 ERBB2 FBXW7
10	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	13.1	AKT1 CREBBP EP300 FGFR3 KRAS TP53
11	ESR-mediated signaling ⁶⁶ Show member pathways Estrogen-dependent gene expression ⁶⁶ RUNX1 regulates estrogen receptor mediated transcription ⁶⁶ Signaling by Nuclear Receptors ⁶⁶	13.02	RXRA PIK3CA KRAS EP300 CREBBP AKT1
12	Signaling by WNT ⁶⁶ Show member pathways TCF dependent signaling in response to WNT ⁶⁶	12.92	KRAS EP300 CTNNB1 CREBBP AKT1
13	CCR5 Pathway in Macrophages ⁶⁴ Show member pathways Androgen Signaling ⁶⁴ Chemokine Signaling ⁶⁴ Chemokine signaling pathway ⁷⁴	12.9	PIK3CA KRAS EP300 CREBBP AKT1
14	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.88	TP53 PIK3CA KRAS EP300 CREBBP AKT1
15	NFAT and Cardiac Hypertrophy ⁶⁴ Show member pathways IGF1R Signaling ⁶⁴ Signaling Involved in Cardiac Hypertrophy ⁶⁴	12.87	PIK3CA KRAS FGFR3 ERBB2 EP300 CREBBP
16	Nuclear events mediated by NFE2L2 ⁶⁶ Show member pathways Cellular response to chemical stress ⁶⁶ Cytoprotection by HMOX1 ⁶⁶ KEAP1-NFE2L2 pathway ⁶⁶ NFE2L2 regulates pentose phosphate pathway genes ⁶⁶ NFE2L2 regulating anti-oxidant/detoxification enzymes ⁶⁶ NFE2L2 regulating TCA cycle genes ⁶⁶ Regulation of BACH1 activity ⁶⁶ Regulation of HMOX1 expression and activity ⁶⁶ Regulation of NFE2L2 gene expression ⁶⁶	12.84	AKT1 CDKN2A CREBBP EP300 RXRA
17	Pre-NOTCH Expression and Processing ⁶⁶ Show member pathways Defective LFNG causes SCDO3 ⁶⁶ Pre-NOTCH Processing in Golgi ⁶⁶ Pre-NOTCH Processing in the Endoplasmic Reticulum ⁶⁶ Pre-NOTCH Transcription and Translation ⁶⁶ Signaling by NOTCH ⁶⁶	12.81	TP53 FBXW7 EP300 CREBBP AKT1
18	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.81	PIK3CA KRAS FGFR3 ERBB2 EP300 CTNNB1
19	fMLP Pathway ⁶⁴ Show member pathways CXCR4 Pathway ⁶⁴ Huntington's Disease Pathway ⁶⁴ Internalin Pathway ⁶⁴ Signal transduction Activation of PKC via G-Protein coupled receptor ²²	12.8	TP53 KRAS CTNNB1 CREBBP AKT1
20	Malignant pleural mesothelioma ⁷⁴	12.72	TP53 PIK3CA FGFR3 CTNNB1 CDKN2A AKT1
21	G-Beta Gamma Signaling ⁶⁴ Show member pathways CRHR Pathway ⁶⁴ GHRH Signaling ⁶⁴	12.7	KRAS EP300 CREBBP CDKN2A AKT1
22	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.68	TP53 PIK3CA KRAS FGFR3 AKT1
23	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.61	TP53 PIK3CA KRAS ERBB2 CTNNB1 AKT1
24	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.5	TP53 PIK3CA ERBB2 CTNNB1 AKT1
25	WNT Signaling ⁶⁴	12.47	TP53 CTNNB1 CREBBP AKT1
26	MAPK signaling pathway ⁷⁴	12.45	TP53 KRAS FGFR3 AKT1
27	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.45	PIK3CA KRAS CTNNB1 AKT1
28	Development FGFR signaling pathway ²² Show member pathways Development FGF-family signaling ²² Development Flt3 signaling ²² FGF Pathway ⁶⁴	12.44	PIK3CA KRAS FGFR3 AKT1
29	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.44	TP53 PIK3CA KRAS ERBB2 CTNNB1 AKT1
30	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.43	PIK3CA KRAS FGFR3 ERBB2 CTNNB1
31	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.43	TP53 RXRA PIK3CA KRAS FGFR3 ERBB2
32	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.36	TP53 PIK3CA EP300 AKT1
33	Signaling by VEGF ⁶⁶ Show member pathways VEGFA-VEGFR2 Pathway ⁶⁶	12.35	PIK3CA KRAS CTNNB1 AKT1
34	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.34	TP53 PIK3CA KRAS FGFR3 ERBB2 CTNNB1
35	Focal adhesion ⁷⁴	12.32	PIK3CA ERBB2 CTNNB1 AKT1
36	Ras signaling ⁷⁴	12.29	PIK3CA KRAS FGFR3 AKT1
37	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.28	TP53 PIK3CA KRAS FGFR3 ERBB2 CTNNB1
38	Colorectal Cancer Metastasis ⁶⁴	12.23	TP53 KRAS CTNNB1 AKT1
39	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.23	RXRA PIK3CA ERBB2 EP300 CREBBP AKT1
40	NGF Pathway ⁶⁴ Show member pathways MAPK and NFkB signaling pathways inhibited by Yersinia YopJ ⁷⁴ TRKA Signaling ⁶⁴	12.21	AKT1 CREBBP KRAS TP53
41	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	12.2	TP53 PIK3CA KRAS CTNNB1 AKT1
42	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.19	TP53 PIK3CA CDKN2A AKT1
43	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.19	AKT1 ERBB2 FGFR3 KRAS PIK3CA TP53
44	Integrated breast cancer pathway ⁷⁴	12.14	TP53 KRAS EP300 CTNNB1 AKT1
45	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.12	PIK3CA ERBB2 EP300 CTNNB1 AKT1
46	Ebola virus infection in host ⁷⁴	12.1	PIK3CA EP300 CREBBP AKT1
47	Signaling by ERBB2 ⁶⁶ Show member pathways Downregulation of ERBB2 signaling ⁶⁶ Downregulation of ERBB2:ERBB3 signaling ⁶⁶ ERBB2 Activates PTK6 Signaling ⁶⁶ ERBB2 Regulates Cell Motility ⁶⁶ GRB7 events in ERBB2 signaling ⁶⁶	12.09	PIK3CA KRAS ERBB2 AKT1
48	mTOR Signaling ⁶⁵	12.08	TP53 KRAS FGFR3 ERBB2 AKT1
49	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	12.07	TP53 PIK3CA ERBB2 AKT1
50	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²²	12.02	PIK3CA KRAS ERBB2 AKT1

Sources

GO Terms for Bladder Urothelial Carcinoma

Cellular components related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	transcription regulator complex	GO:0005667	9.32	TP53 RXRA EP300 CTNNB1 CREBBP

Biological processes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	10.09	TP53 PIK3CA FBXW7 CTNNB1 AKT1
2	phosphatidylinositol 3-kinase signaling	GO:0014065	9.88	PIK3CA ERBB2 AKT1
3	rhythmic process	GO:0048511	9.8	TP53 FBXW7 EP300 CREBBP
4	N-terminal peptidyl-lysine acetylation	GO:0018076	9.56	CREBBP EP300
5	vasculature development	GO:0001944	9.55	PIK3CA FBXW7 CTNNB1
6	negative regulation of immature T cell proliferation in thymus	GO:0033088	9.54	ERBB2 CDKN2A
7	protein destabilization	GO:0031648	9.5	FBXW7 EP300 CREBBP CDKN2A
8	positive regulation of gene expression	GO:0010628	9.4	TP53 PVT1 KRAS ERBB2 EP300 CTNNB1

Molecular functions related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nuclear receptor binding	GO:0016922	9.8	RXRA EP300 CTNNB1
2	transcription coregulator binding	GO:0001221	9.73	RXRA EP300 CTNNB1
3	RNA polymerase II-specific DNA-binding transcription factor binding	GO:0061629	9.61	TP53 EP300 CTNNB1 CREBBP CDKN2A
4	disordered domain specific binding	GO:0097718	9.55	TP53 CTNNB1 CDKN2A
5	peptide N-acetyltransferase activity	GO:0034212	8.92	EP300 CREBBP